We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-9.15%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.68B
AUM Growth
-$780M
Cap. Flow
-$238M
Cap. Flow %
-14.17%
Top 10 Hldgs %
50.05%
Holding
96
New
8
Increased
9
Reduced
34
Closed
18

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$34.2M
2
VERV
Verve Therapeutics
VERV
+$16.8M
3
VTYX
Ventyx Biosciences
VTYX
+$14.9M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$14M
5
TNGX icon
Tango Therapeutics
TNGX
+$12M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$50.6M
2
AGEN
Agenus
AGEN
+$25.2M
3
RVMD icon
Revolution Medicines
RVMD
+$20.1M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$18.7M
5
ASND icon
Ascendis Pharma A/S
ASND
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
51
Pliant Therapeutics
PLRX
$65M
$6.51M 0.39%
482,413
– –
ALGS icon
52
Aligos Therapeutics
ALGS
$34.9M
$6.19M 0.37%
20,850
-5,837
-22% -$2.13M
VRDN icon
53
Viridian Therapeutics
VRDN
$2.67B
$5.93M 0.35%
300,000
-42,562
-12% -$793K
ELDN icon
54
Eledon Pharmaceuticals
ELDN
$285M
$5.75M 0.34%
1,305,095
– –
YMAB
55
DELISTED
Y-mAbs Therapeutics
YMAB
$4.86M 0.29%
300,000
-200,000
-40% -$4.27M
CABA icon
56
Cabaletta Bio
CABA
$455M
$4.38M 0.26%
1,154,424
-457,199
-28% -$4.88M
MLTX icon
57
MoonLake Immunotherapeutics
MLTX
$1.55B
$4.25M 0.25%
430,000
– –
HARP
58
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$4.08M 0.24%
54,060
– –
CLDX icon
59
Celldex Therapeutics
CLDX
$3.28B
$3.86M 0.23%
+100,000
New +$4.36M
RCOR
60
DELISTED
Renovacor, Inc.
RCOR
$3.85M 0.23%
500,000
– –
MGTX icon
61
MeiraGTx Holdings
MGTX
$1.21B
$3.56M 0.21%
+150,000
New +$2.87M
ANAB icon
62
AnaptysBio
ANAB
$1.68B
$3.48M 0.21%
100,000
-285,081
-74% -$9.04M
AKUS
63
DELISTED
Akouos Inc
AKUS
$3.35M 0.2%
394,500
– –
MRUS
64
DELISTED
Merus
MRUS
$3.18M 0.19%
100,000
-150,000
-60% -$4.24M
DMRA
65
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$3.09M 0.18%
40,810
-5,219
-11% -$410K
ATXS
66
DELISTED
Astria Therapeutics
ATXS
$2.98M 0.18%
552,903
– –
DTIL icon
67
Precision BioSciences
DTIL
$207M
$2.56M 0.15%
11,551
– –
LENZ
68
LENZ Therapeutics
LENZ
$168M
$2.52M 0.15%
29,022
– –
GOSS icon
69
Gossamer Bio
GOSS
$87M
$2.24M 0.13%
198,382
– –
AUTL
70
Autolus Therapeutics
AUTL
$562M
$2.04M 0.12%
392,167
– –
QURE icon
71
uniQure
QURE
$3.22B
$1.04M 0.06%
50,000
-189,548
-79% -$5.44M
CNTB
72
Connect Biopharma Holdings
CNTB
$139M
$1.03M 0.06%
200,000
-300,000
-60% -$3.33M
SONX
73
DELISTED
Sonendo, Inc.
SONX
$859K 0.05%
+149,200
New +$1.34M
BCEL
74
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$829K 0.05%
273,500
– –
ORTX
75
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$339K 0.02%
25,665
– –
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Cormorant Asset Management held 96 positions worth $1.68B, down 32% from $2.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cormorant Asset Management withdrew a net $238M in Q4 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was Agenus, an estimated $25.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Ventyx Biosciences worth $15.1M.

  • Cormorant Asset Management's largest Q4 2021 buy was Ventyx Biosciences: 785,303 shares worth $15.1M.
  • Cormorant Asset Management added most to Beam Therapeutics in Q4 2021, an estimated $34.2M increase.
  • Cormorant Asset Management's biggest Q4 2021 reduction was Atea Pharmaceuticals, cutting an estimated $50.6M.
  • Cormorant Asset Management fully exited Agenus in Q4 2021, selling an estimated $25.2M.
  • Cormorant Asset Management's ten largest holdings make up 50% of its $1.68B portfolio in Q4 2021.
  • Cormorant Asset Management opened 8 new positions and closed 18 in Q4 2021.
  • Cormorant Asset Management's portfolio value fell 32% quarter-over-quarter to $1.68B.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.